

Abbott Laboratories (ABT)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000001800

Abbott Laboratories	
ABT; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 54.6; sampling error 2.5 points; lower is stronger
Rank	203 of 371
Profitability	B/C percentile 41.4
Solvency	C percentile 54.9
Growth and financing	C percentile 52.4
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$86.7B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	11 of 14
Graded from	filings received through Feb 20, 2026 231 days before the rescans; latest periodic filing 10-Q received Jul 28, 2026
Last close	\$98.49 2026-10-08; market equity \$171.6B
Price used in grade	None



C, the tortoise

middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B from Feb 21, 2024, C from Feb 21, 2025, C/D from Mar 21, 2025, C from Apr 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 20, 2026

Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and

obtaining the required regulatory clearances.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 41.4						
Gross profitability		28.8%	32.2%	51.8	372	2025-12-31
Return on invested capital		11.2%	9.3%	39.7	74	2025-12-31
Accruals ratio		(3.6%)	(6.6%)	68.5	811	2025-12-31
Gross margin stability, five years		0.7 pts	2.8 pts	5.8	243	2025-12-31
Solvency, sleeve percentile 54.9						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-03-31
Altman Z double-prime		not computable	(0.31)			one or more required annual facts are missing
Net debt to EBITDA		0.46x	1.82x	31.1	75	2025-12-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		1.58x	2.96x	78.8	839	2025-12-31
Growth and financing, sleeve percentile 52.4						
Revenue growth, three-year compound		0.5%	10.0%	69.8	415	2025-12-31
Free cash flow growth, three-year compound		(1.8%)	10.9%	75.8	96	2025-12-31
Reinvestment rate		11.9%	37.1%	62.1	104	2025-12-31
Asset growth, three years		5.2%	2.1%	40.3	704	2025-12-31
Net share issuance, one year		0.2%	2.5%	14.1	634	2026-01-31

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
198	Perrigo Co. plc (PRGO)	53.2	C	
199	Sotera Health Co. (SHC)	53.5	C	
200	Universal Health Services Inc. (UHS)	53.8	C	
201	Roivant Sciences Ltd. (ROIV)	54.1	C	fortress
				balance sheet
202	Emergent BioSolutions Inc. (EBS)	54.3	C	

203	Abbott Laboratories (ABT) <	54.6	C
204	Teladoc Health, Inc. (TDOC)	54.9	C fortress balance sheet
205	Neuronetics, Inc. (STIM)	55.1	C
206	Regenxbio Inc. (RGNX)	55.4	C short runway
207	ELI Lilly & Co. (LLY)	55.7	C
208	Cabaletta Bio, Inc. (CABA)	55.9	C dilution

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(15.7%)	8.0%	34
Distance from 52-week high	(26.6%)	(31.4%)	56
EBIT to enterprise value	4.5%	(1.5%)	75
Free cash flow yield	4.3%	(1.0%)	78
Book value to price	0.30	0.28	51
Sales to price	0.26	0.31	45
Composite equity issuance, five years	(12.2%)	20.3%	14
Relative strength against the sector, log excess return	(0.38)	(0.14)	34

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$6.8B
Operating cash flow, four quarters	\$9.5B
Months of runway	not finite
Days since last periodic filing	73 (10-Q received Jul 28, 2026)
Median daily dollar volume, 63 sessions	\$861.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$44.3B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$19.3B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
3	assets	us-gaap:Assets	\$86.7B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
4	operating income	us-gaap:OperatingIncomeLoss	\$8.1B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$8.5B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1.9B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
7	total debt	us-gaap:LongTermDebt	\$12.9B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
8	book equity	us-gaap:StockholdersEquity	\$52.1B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$8.5B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
10	total debt	us-gaap:LongTermDebt	\$14.1B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
11	book equity	us-gaap:StockholdersEquity	\$47.7B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$7.6B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
13	net income	us-gaap:NetIncomeLoss	\$6.5B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$9.6B	2025-12-31	2026-02-20	10-K	0001628280-26-010185

15	assets	us-gaap:Assets	\$81.4B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$42.0B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$18.7B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$40.1B	2023-12-31	2026-02-20	10-K	0001628280-26-010185
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$18.0B	2023-12-31	2026-02-20	10-K	0001628280-26-010185
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$43.7B	2022-12-31	2025-02-21	10-K	0001628280-25-007110
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$19.1B	2022-12-31	2025-02-21	10-K	0001628280-25-007110
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$43.1B	2021-12-31	2024-02-16	10-K	0001628280-24-005348
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$18.5B	2021-12-31	2024-02-16	10-K	0001628280-24-005348
24	depreciation amortization	us-gaap:Depreciation	\$1.4B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
25	operating income	us-gaap:OperatingIncomeLoss	\$6.5B	2023-12-31	2026-02-20	10-K	0001628280-26-010185
26	interest expense	us-gaap:InterestExpense	\$637.0M	2023-12-31	2024-02-16	10-K	0001628280-24-005348
27	current assets	us-gaap:AssetsCurrent	\$26.0B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
28	current liabilities	us-gaap:LiabilitiesCurrent	\$16.5B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.2B	2025-12-31	2026-02-20	10-K	0001628280-26-010185
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.6B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.2B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$7.3B	2023-12-31	2026-02-20	10-K	0001628280-26-010185
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.2B	2023-12-31	2026-02-20	10-K	0001628280-26-010185
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$9.6B	2022-12-31	2025-02-21	10-K	0001628280-25-007110
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.8B	2022-12-31	2025-02-21	10-K	0001628280-25-007110
36	current assets	us-gaap:AssetsCurrent	\$23.7B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
37	current liabilities	us-gaap:LiabilitiesCurrent	\$14.2B	2024-12-31	2026-02-20	10-K	0001628280-26-010185
38	assets	us-gaap:Assets	\$73.2B	2023-12-31	2025-02-21	10-K	0001628280-25-007110
39	assets	us-gaap:Assets	\$74.4B	2022-12-31	2024-02-16	10-K	0001628280-24-005348
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,737,682,887	2026-01-31	2026-02-20	10-K	0001628280-26-010185
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,734,323,411	2025-01-31	2025-02-21	10-K	0001628280-25-007110